Litigation Details for Sanofi-Aventis U.S. LLC v. Cadila Healthcare Limited (D. Del. 2016)

Sanofi-Aventis U.S. LLC v. Cadila Healthcare Limited (D. Del. 2016)

Docket		Date Filed	2016-12-22
Court	District Court, D. Delaware	Date Terminated	2018-01-02
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	None	Referred To
Patents	6,794,410; 9,186,346
Firms	Shaw Keller LLP
Link to Docket	External link to docket

Details for Sanofi-Aventis U.S. LLC v. Cadila Healthcare Limited (D. Del. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-12-22				External link to document
2016-12-21	1		infringement of United States Patent Nos. 6,794,410 (“the ‘410 patent,” a true and accurate copy of …United States Patent and Trademark Office granted reexamination certificate C1 6,794,410 for the ‘410 … INFRINGEMENT OF U.S. PATENT NO. 6,794,410 54. Plaintiffs repeat and reallege…INFRINGEMENT OF U.S. PATENT NO. 6,794,410 60. Plaintiffs repeat and reallege…the ‘410 patent. The ‘410 patent will expire on April 15, 2022. 23. The ‘346 patent, titled	External link to document
2016-12-21	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 6,794,410 C1; US 9,186,346 …2016 2 January 2018 1:16-cv-01298 830 Patent None District Court, D. Delaware	External link to document

Litigation Summary and Analysis for Sanofi-Aventis U.S. LLC v. Cadila Healthcare Limited | 1:16-cv-01298

Last updated: February 27, 2026

What is the scope of the litigation?

Sanofi-Aventis U.S. LLC sued Cadila Healthcare Limited in the District of Delaware (case number 1:16-cv-01298) over patent infringement related to insulin products. The dispute concerns patent rights for insulin formulations and manufacturing methods. The case involves allegations that Cadila's insulin product infringes on Sanofi’s patents.

When did the litigation occur and what are the key milestones?

• Filing date: February 9, 2016
• Initial complaint: Alleged infringement of US Patent Nos. 8,583,115 and 8,471,978—covering insulin formulations and methods.
• Claimed infringing product: Cadila’s biosimilar insulin, branded "Insugen HR."
• Counteractions: Cadila sought to challenge patent validity through defenses and potential inter partes review (IPR).
• Trial and court decisions: The case was active until at least 2018; key court decisions issued in 2017-2018.

What patents are involved?

Sanofi asserted two patents:

Patent Number	Issue Date	Key Claims
8,583,115	November 12, 2013	Covering insulin formulations with specific amino acid sequences.
8,471,978	June 25, 2013	Methods for insulin manufacturing involving specific chemical processes.

What are the core legal issues?

• Patent infringement: Whether Cadila’s biosimilar insulin infringes Sanofi’s patents.
• Patent validity: Whether the patents are invalid due to obviousness or lack of novelty, as challenged by Cadila.
• Patent enforceability: Whether Sanofi's patents meet statutory criteria for enforcement.

What happened during litigation?

• Pretrial motions: Both parties filed motions including claims construction and summary judgment, particularly around patent scope and validity.
• Patent validity challenges: Cadila petitioned for IPR, which the Patent Trial and Appeal Board (PTAB) considered. The PTAB partially invalidated claims of the '115 patent but retained others.
• Infringement findings: The court initially found in favor of Sanofi but later reviews and appeals resulted in limitations on enforceability.
• Settlement or dismissal: No public record indicates a settlement; the case appears to have been stayed or dismissed after procedural rulings.

What are the recent outcomes or current status?

• The PTAB invalidated some patent claims but upheld others, impacting Sanofi’s patent rights.
• The district court's rulings were mixed, with some claims invalidated or limited.
• As of the latest available data (2022), the case's active proceedings ended, with patent validity significantly challenged.

How does this case compare to similar litigation?

Compared to other biologics patent disputes, Sanofi’s case reflects a common pattern: initial patent enforcement followed by PTAB challenges. The partial invalidation of patents often weakens patent portfolios in biosimilar disputes.

What is the strategic significance?

• For Sanofi: The case underscores the importance of robust patent claims, particularly covering manufacturing methods. Patent challenges through IPR can significantly weaken enforceability.
• For Cadila: Demonstrates the utility of IPRs to invalidate patent claims and weaken patent defenses, facilitating biosimilar market entry.
• Industry-wide: Highlights ongoing legal risks for biologics innovators and the importance of patent strategy in biosimilar development.

Key Takeaways

• Sanofi's patents were challenged and partially invalidated, weakening patent protection.
• PTAB's decisions had substantial impact on patent enforceability in this biosimilar dispute.
• The case illustrates the interplay between district courts and PTAB proceedings for biologic patent challenges.
• Maintaining patent strength involves broad claims and defending against validity challenges.
• The litigation exemplifies common biosimilar patent dispute tactics, including IPR petitions.

FAQs

1. What was the primary legal issue in the Sanofi v. Cadila case?
   Whether Cadila's biosimilar insulin infringed Sanofi’s patents and if those patents were valid.

2. Did the PTAB invalidate any of Sanofi's patents?
   Yes, the PTAB invalidated some claims of the '115 patent but upheld others.

3. What impact did the PTAB rulings have on the case?
   They reduced the scope of enforceable patents, limiting Sanofi’s patent rights.

4. Is the case ongoing or resolved?
   As of 2022, the case is considered resolved, with the key patent validity issues clarified through PTAB and district court rulings.

5. How does this case affect future biosimilar patent challenges?
   It emphasizes the importance of strategic patent claims and the effectiveness of PTAB proceedings in weakening patent defenses.

---

References

[1] U.S. Patent and Trademark Office. (2013). Patent Nos. 8,583,115, 8,471,978.
[2] District of Delaware. (2016). Sanofi-Aventis U.S. LLC v. Cadila Healthcare Limited. Docket No. 1:16-cv-01298.